Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years

Heidenreich, 2014, EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013, Eur Urol, 65, 124, 10.1016/j.eururo.2013.09.046 Mullins, 2012, The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary, J Urol, 188, 2219, 10.1016/j.juro.2012.08.028 Eggener, 2011, Predicting 15-year prostate cancer specific mortality after radical prostatectomy, J Urol, 185, 869, 10.1016/j.juro.2010.10.057 Boorjian, 2011, Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence, Eur Urol, 59, 893, 10.1016/j.eururo.2011.02.026 Suardi, 2008, A nomogram predicting long-term biochemical recurrence after radical prostatectomy, Cancer, 112, 1254, 10.1002/cncr.23293 Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 Gandaglia, 2014, Distribution of metastatic sites in patients with prostate cancer: a population-based analysis, Prostate, 74, 210, 10.1002/pros.22742 Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Pond, 2014, The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, 65, 3, 10.1016/j.eururo.2013.09.024 Yossepowitch, 2007, The natural history of noncastrate metastatic prostate cancer after radical prostatectomy, Eur Urol, 51, 940, 10.1016/j.eururo.2006.10.045 Hotte, 2010, Current management of castrate-resistant prostate cancer, Curr Oncol, 17, S72, 10.3747/co.v17i0.718 Karantanos, 2013, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, Oncogene, 32, 5501, 10.1038/onc.2013.206 Sharifi, 2005, Androgen deprivation therapy for prostate cancer, JAMA, 294, 238, 10.1001/jama.294.2.238 Conteduca, 2013, The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy, Crit Rev Oncol Hematol, 86, 42, 10.1016/j.critrevonc.2012.09.008 Keating, 2013, Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?, Eur Urol, 64, 159, 10.1016/j.eururo.2012.04.035 Rigatti, 2011, Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography, Eur Urol, 60, 935, 10.1016/j.eururo.2011.07.060 Jilg, 2012, Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer, J Urol, 188, 2190, 10.1016/j.juro.2012.08.041 Winter, 2010, First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy, Urol Int, 84, 418, 10.1159/000296298 Rinnab, 2008, [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study, Urol Int, 81, 191, 10.1159/000144059 Berkovic, 2013, Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy, Clin Genitourin Cancer, 11, 27, 10.1016/j.clgc.2012.08.003 De Bari, 2014, Salvage therapy of small volume prostate cancer nodal failures: a review of the literature, Crit Rev Oncol Hematol, 90, 24, 10.1016/j.critrevonc.2013.11.003 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012 Giovacchini, 2014, 11C-Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy, J Nucl Med., 55, 233, 10.2967/jnumed.113.123380 Sheets, 2013, Trends in the use of postprostatectomy therapies for patients with prostate cancer: a Surveillance, Epidemiology, and End Results Medicare analysis, Cancer, 119, 3295, 10.1002/cncr.28222 Boorjian, 2012, Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy, J Urol, 188, 1761, 10.1016/j.juro.2012.07.037 Antonarakis, 2011, Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database, BJU Int, 108, 378, 10.1111/j.1464-410X.2010.09878.x Picchio, 2011, The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer, Eur Urol, 59, 51, 10.1016/j.eururo.2010.09.004 von Eyben, 2014, Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer, Nucl Med Commun, 35, 221, 10.1097/MNM.0000000000000040 Evangelista, 2013, Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis, Clin Nucl Med, 38, 305, 10.1097/RLU.0b013e3182867f3c Scattoni, 2007, Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy, Eur Urol, 52, 423, 10.1016/j.eururo.2007.03.032 Ceci, 2013, 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study, Clin Nucl Med, 38, e279, 10.1097/RLU.0b013e3182952c4c Fuccio, 2011, Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study, Eur J Nucl Med Mol Imag, 38, 1985, 10.1007/s00259-011-1867-0 Henninger, 2012, [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy—a preliminary study, Nucl Med Commun, 33, 889, 10.1097/MNM.0b013e328355990f Giovacchini, 2010, Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy, Eur J Nucl Med Mol Imaging, 37, 301, 10.1007/s00259-009-1253-3 Giovacchini, 2008, [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy, Eur J Nucl Med Mol Imaging, 35, 1065, 10.1007/s00259-008-0716-2 Schiavina, 2014, First case of F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative C-choline PET/CT: new imaging techniques may expand pioneering approaches, Urol Int, 92, 242, 10.1159/000354730 Non-systematic treatment for patients with low-volume metastatic prostate cancer. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01558427?term=NCT01558427&rank=1. 2013. Accessed December 8, 2013.